Endo Health Solutions
The 10-second takeaway
For the quarter ended March 31 (Q1), Endo Health Solutions missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased slightly. Non-GAAP earnings per share expanded significantly. GAAP earnings per share expanded.
Margins increased across the board.
Endo Health Solutions booked revenue of $708.5 million. The 18 analysts polled by S&P Capital IQ anticipated sales of $741.3 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.09. The 18 earnings estimates compiled by S&P Capital IQ predicted $1.08 per share. Non-GAAP EPS of $1.09 for Q1 were 25% higher than the prior-year quarter's $0.87 per share. GAAP EPS were $0.14 for Q1 against -$0.75 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 59.6%, much better than the prior-year quarter. Operating margin was 20.4%, much better than the prior-year quarter. Net margin was 2.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $751.0 million. On the bottom line, the average EPS estimate is $1.22.
Next year's average estimate for revenue is $2.90 billion. The average EPS estimate is $4.49.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 417 members out of 439 rating the stock outperform, and 22 members rating it underperform. Among 137 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Endo Health Solutions a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $32.53.
- Add Endo Health Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.